| HOME >> BIOLOGY >> TECHNOLOGY |
LOS ANGELES, March 17 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) announced earlier today that it has received several formal purchase and financial commitments with respect to acquisitions of the Company's technology licenses, devices and services. These commitments have come internationally, including in Japan, other parts of Asia and Europe, as well as domestically.
Dr. Harmison, the Company's President and CEO, stated: "I anticipate closing these transactions in the upcoming two to four weeks, which comprise significant business for the Company. With the experiential base developed during my tenure regarding the ECG data generated from the usage of our technologies -- not only by health care providers but also through numerous Athletes for Life-sponsored mobile health care screenings -- there are now numerous additional revenue streams that have naturally become available to the Company. Indeed, physicians have provided me with a variety of data and information following very successful screenings this past weekend on the Athletes for Life Mobile Health Center in Temecula, California. With this kind of data garnered from real patients in the field, the foundation for the expansion of our life-saving devices becomes stronger every day."
The Company did not state the exact amount of business contemplated by these developments, and it cautioned that there is no certainty that any of the transactions will close as contemplated -- or at all.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.
Signalife is publicly traded on the American Stock Exchange under the
symbol SGN. The website for the company is
| SOURCE Signalife, Inc. Copyright©2008 PR Newswire. All rights reserved |